VBI Vaccines, Inc. (NASDAQ:VBIV) Director Steven Gillis bought 300,000 shares of the stock in a transaction on Monday, October 30th. The stock was purchased at an average cost of $3.05 per share, with a total value of $915,000.00. Following the completion of the purchase, the director now directly owns 46,916 shares in the company, valued at approximately $143,093.80. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

COPYRIGHT VIOLATION NOTICE: “VBI Vaccines, Inc. (VBIV) Director Buys $915,000.00 in Stock” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/vbi-vaccines-inc-vbiv-director-buys-915000-00-in-stock/1674833.html.

Hedge funds have recently added to or reduced their stakes in the company. California State Teachers Retirement System acquired a new stake in shares of VBI Vaccines during the second quarter valued at approximately $167,000. Schwab Charles Investment Management Inc. acquired a new stake in shares of VBI Vaccines during the second quarter valued at approximately $187,000. Bank of New York Mellon Corp acquired a new stake in shares of VBI Vaccines during the second quarter valued at approximately $193,000. Teachers Advisors LLC acquired a new stake in shares of VBI Vaccines during the second quarter valued at approximately $195,000. Finally, TIAA CREF Investment Management LLC acquired a new stake in shares of VBI Vaccines during the second quarter valued at approximately $262,000. Institutional investors and hedge funds own 31.50% of the company’s stock.

VBIV has been the subject of several recent analyst reports. Zacks Investment Research raised shares of VBI Vaccines from a “sell” rating to a “hold” rating in a research note on Tuesday, September 5th. ValuEngine raised shares of VBI Vaccines from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. Noble Financial reaffirmed a “buy” rating on shares of VBI Vaccines in a research note on Monday, July 31st. Finally, Canaccord Genuity initiated coverage on shares of VBI Vaccines in a research note on Wednesday. They issued a “buy” rating and a $10.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the stock. VBI Vaccines currently has a consensus rating of “Hold” and an average price target of $10.00.

VBI Vaccines Company Profile

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

Receive News & Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.